IP Library Granted Patent US 10,786,564
Granted Patent B2
US 10,786,564 · App. 15/771,029 · Granted Sep 29, 2020

MDCK suspension cell lines in serum-free, chemically-defined media for vaccine production

Inventors: Jenny Bang (Santa Ana, CA); Hsiao-Tzu Ni (Santa Ana, CA); Alan Yung-Chih Hu (Zhunan Town, TW); Tsai-Chuan Weng (Zhunan Town, TW)
Assignees: NATIONAL HEALTH RESEARCH INSTITUTES; FUJIFILM IRVINE SCIENTIFIC, INC.
A61K39/145A61K39/12C12N5/0686C12N7/00C12N15/8509A61P31/16C12N2015/8518C12N2500/90C12N2500/99C12N2511/00C12N2513/00C12N2517/02C12N2760/16034C12N2760/16051C12N2760/16134C12N2760/16151C12N2760/16251
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,786,564
App. No.
15/771,029
Granted
Sep 29, 2020
Kind
B2
Abstract

Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.

Claims (17)

1. A composition comprising adapted Madin-Darby canine kidney (MDCK) cells and a growth medium, the growth medium comprising a chemically-defined and animal component free medium, wherein the adapted MDCK cells are in suspension culture without microcarriers, wherein the chemically defined medium sustains cell growth and expansion without medium exchange or subculture, further wherein the adapted MDCK cells are deposited as DSM ACC3309 with Leibniz-Institut DSMZ-Deutsche Sammlung von Mikro-organismen and Zellkulturen GmbH.

2. The composition of claim 1 , wherein the adapted MDCK cells have an average doubling time of between about 30 hours and about 35 hours.

3. The composition of claim 1 , wherein the adapted MDCK cells are suitable for producing a virus for a vaccine, further wherein the virus maintains antigenicity.

4. A method for producing a virus for vaccine production in adapted Madin-Darby canine kidney (MDCK) cells, said adapted MDCK cells being capable of being cultured in suspension without microcarriers, said method comprising contacting the adapted MDCK cells with a chemically-defined and animal component free growth medium, infecting the cells with a virus, and harvesting the virus, wherein the chemically defined medium sustains cell growth and expansion without medium exchange or subculture, and further wherein the adapted MDCK cells are deposited as DSM ACC3309 with Leibniz-Institut DSMZ-Deutsche Sammlung von Mikro-organismen and Zellkulturen GmbH.

5. A method for producing Madin-Darby canine kidney (MDCK) cells that are capable of being cultured in suspension without microcarriers in a chemically-defined medium without serum, said method comprising:

a) providing adherent MDCK cells;

b) culturing the adherent MDCK cells in a growth medium comprising serum in a stirred bioreactor and in the absence of microcarriers for a period of time sufficient for the MDCK cells to adapt to suspension culture; and

c) culturing the suspension-adapted MDCK cells in suspension culture in a chemically-defined medium and without serum, thereby providing MDCK cells that are capable of being cultured in suspension without microcarriers in a chemically-defined medium without serum,

wherein the chemically defined medium sustains cell growth and expansion without medium exchange or subculture, further wherein the adapted MDCK cells are deposited as DSM ACC3309 with Leibniz-Institut DSMZ-Deutsche Sammlung von Mikro-organismen and Zellkulturen GmbH.

6. The method of claim 5 , wherein the growth medium comprises between about 1% and about 10% serum.

7. The method of claim 6 , wherein the growth medium comprises about 5% serum.

8. The method of claim 5 , wherein the MDCK cells are cultured in the presence of 5% CO 2 in steps b) and c).

9. The method of claim 5 , wherein the adapted MDCK cells have an average doubling time of between about 30 hours and about 35 hours.

10. The method of claim 5 , wherein the adapted MDCK cells are suitable for producing virus for a human vaccine, further wherein a virus is produced and the virus maintains antigenicity.

11. A composition comprising adapted MDCK cells produced by the method of claim 5 .

12. The composition of claim 11 , wherein the adapted MDCK cells have an average doubling time of between about 30 hours and about 35 hours.

13. The composition of claim 11 , wherein the adapted MDCK cells are suitable for producing virus for a human vaccine, further wherein the virus maintains antigenicity.

Assignments (4)
CHANGE OF NAME Recorded Dec 15, 2025
From: FUJIFILM IRVINE SCIENTIFIC, INC.
To: FUJIFILM BIOSCIENCES INC.
Reel/Frame 073950/0786 →
CHANGE OF NAME Recorded Aug 12, 2019
From: IRVINE SCIENTIFIC SALES COMPANY, INC.
To: FUJIFILM IRVINE SCIENTIFIC, INC.
Reel/Frame 050032/0637 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2018
From: HU, ALAN YUNG-CHIH; WENG, TSAI-CHUAN
To: NATIONAL HEALTH RESEARCH INSTITUTES
Reel/Frame 045862/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2018
From: BANG, JENNY; NI, HSIAO-TZU
To: IRVINE SCIENTIFIC SALES COMPANY, INC.
Reel/Frame 045862/0691 →
Continuity (2)
Provisional Application 62248954 · Oct 30, 2015
Related Publication 20180311337A1 · Nov 1, 2018